At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Hypertension (HPT) is defined as a persistent elevation of systolic blood pressure (BP) of 140 mmHg or greater and/or diastolic BP of 90 mmHg or greater, taken at least twice ontwo separate occasions. The most recent National Health and Morbidity Survey (NHMS) 2015 that focuses on noncommunicable diseases showed that among adults aged 18 years and older, there was an increase in the prevalence of HPT from 33.6% in 2011 to 35.3%. While the proportion of patients with HPT who have attained good BP control has increased from 34.7% in 2011 to 37.4%, the awareness of the condition among patients remains poor. The prevalence of undiagnosed HPT remains high; hence, it is recommended that every adult aged 18 years and older to check their BP at least once annually, and more frequently in those with risk factors (eg, family history, obese).
At the recent 10th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress(MAC) held in Hilton Kuala Lumpur, Dr Wong Ming, a consultant endocrinologist from Sunway Medical Centre, spoke on the role of non–high-density lipoprotein cholesterol (non–HDL-c) as an emerging marker and treatment target for cardiovascular (CV) disease. Additionally, she also highlighted the role of fenofibrate in delaying and preventing diabetic retinopathy (DR).
Prof. Rafael R. Castillo, Dr. Hyo Seung Ahn, 20190820000000
Major trials have demonstrated the benefits of beta-blockers in the treatment of hypertension.1 At a recent symposium held during the Asian Paciﬁc Society of Cardiology 2019 Congress in Manila, Philippines, experts discussed the latest guidelines on hypertension treatment, with a focus on the role of the 3rd generation beta-blocker, nebivolol. The symposium was chaired by Dr Dante D. Morales, Clinical Associate Professor at the University of the Philippines College of Medicine, and featured renowned cardiologists Prof Rafael R. Castillo and Dr Hyo Seung Ahn.
Coenzyme Q10 (CoQ10, ubiquinone) is a fat-soluble, potent physiological antioxidant that is required for the production of cellular adenosine triphosphate (ATP). CoQ10 can be obtained through tissue synthesis and diet, and it has been widely studied in patients with cardiovascular (CV) risk factors. The effects of oral CoQ10 supplementation in different patient subgroups are presented here.
At the recent 12th IDF-WPR Congress and 10th AASD Scientific Meeting held at Kuala Lumpur Convention Centre, the importance of glycaemic control and the practical management of type 2 diabetes mellitus (T2DM) were highlighted by two international speakers, Dr Sanjay Kalra from India and Professor Jean Claude Mbanya from Cameroon.
At a webinar hosted by Pfizer, leading Malaysian family medicine specialists Professor Chia Yook Chin andProfessor Sherina Mohd Sidik discussed a host of issues commonly encountered in primary care, includingpreventing cardiovascular (CV) disease, pain control in osteoarthritis (OA) and depression management.
Dr. Choo Gim Hooi, Assoc Prof. Pattarapong Makarawate, Dr. Krisada Sastravaha, 20181217100000
Coronary artery disease (CAD) is a leading cause of mortality and morbidity globally and its burden is expected to increase due to the rising prevalence of risk factors such as hypertension, diabetes, and dyslipidaemia. In conjunction with the 23rd ASEAN Federation of Cardiology Congress held in Bangkok, Thailand, Menarini organized a lunch symposium and product theatre to discuss the significance of optimal medical therapy (OMT) in the management of stable CAD, with a focus on the role of ranolazine (Ranexa®).
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
Through a cardiology webcast co-hosted by Pfizer, the National Heart Association of Malaysia (NHAM), and the American College of Cardiology (ACC), Dr Ong Mei Lin, Dr Aaron D. Kugelmass and Dr Tracy Wang shared their insights into the importance of secondary prevention measures in reducing the burden of atherosclerotic cardiovascular disease (ASCVD).
The inclusion of two proanthocyanidin (PA)-rich apples into normal diets improves cardiovascular disease (CVD) risk factors by reducing total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and intercellular cell adhesion molecule-1 (ICAM-1), as well as increasing microvascular vasodilation, in individuals with mildly elevated serum cholesterol concentrations, a recent study has shown.
In acutely ill medical patients, asymptomatic proximal deep-vein thrombosis (ASxDVT), as assessed via compression ultrasonography, is associated with an elevated risk of all-cause mortality, according to a post hoc analysis of the MAGELLAN* trial presented at ASH 2019.
Luspatercept promotes red blood cell (RBC) transfusion independence among low-risk myelodysplastic syndrome (MDS) patients, according to a longer-term analysis of the MEDALIST study presented at the recently concluded 61st Annual Meeting and Exposition of the American Society of Hematology (ASH 2019).